STOCK TITAN

[144] Ginkgo Bioworks Holdings, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Ginkgo Bioworks (DNA) Form 144 notice: An insider notified the sale of 10,000 Class A shares through Fidelity Brokerage Services (900 Salem St, Smithfield RI) with an approximate aggregate market value of $109,209.3447,089,598 and an approximate sale date of 09/08/2025. All 10,000 shares were acquired from the issuer as restricted stock vesting on dates between 11/19/2021 and 03/11/2022 and were paid as compensation. The filer reports no securities sold in the past three months.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider plans to sell 10,000 vested Class A shares (~$109k) into the market via Fidelity on 09/08/2025.

The filing is a routine Rule 144 disclosure showing that the shares were acquired through restricted stock vesting and paid as compensation between 2021 and 2022. The total shares to be sold equal the sum of the vesting lots, indicating a disposal of previously restricted holdings rather than newly acquired shares. No prior sales by the filer in the past three months are reported, and the filing contains no material non-public disclosures.

TL;DR: This is a standard insider sale notice with acquisition history disclosed; procedural compliance appears met.

The Form 144 documents the broker, share count, market value, acquisition dates, and that payment was for compensation. It includes the required representation about material non-public information. The filing does not disclose any unusual terms or related-party transfers; it appears to be a routine disclosure under Rule 144.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Ginkgo Bioworks Holdings Inc

NYSE:DNA

DNA Rankings

DNA Latest News

DNA Latest SEC Filings

DNA Stock Data

539.86M
58.30M
6.73%
79.11%
11.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON